<!-- SECTION START: Top (Hero + Intro + Navigation) -->
{% extends "layout.html" %}

{% block title %}Human Practices{% endblock %}
{% block lead %}{% endblock %}

{% block page_content %}

<div class="education-hero hp-banner">
  <div class="education-hero-content-container">
    <h1 class="text-glitch">HUMAN PRACTICES</h1>
  </div>
</div>

<div class="spacer5"></div>

<div class="page-section width-75" id="intro">
  <div class="section-title">
    <h1 style="text-align: left;" class="animate-text-scramble">Introduction</h1>
  </div>

  <p style="text-align: left;">
    In our <strong>Integrated Human Practices</strong>, our goal was to identify and learn from the stakeholders most
    central to our project. We approached this from multiple angles: tracing the creators of <strong>core protocols,
    papers, and patents for <em>K. phaffii</em></strong>; reaching out to <strong>founders of emerging biotech and
    food-tech startups</strong>; consulting those with first-hand experience of pitfalls we anticipated — from <strong>downstream
    bottlenecks to failed ventures</strong> — and engaging with <strong>large protein purification companies and VCs</strong>
    who have seen many ideas like ours and know the common mistakes.
    <br><br>
    <strong>Domain-expert input</strong> became crucial to our <strong>DBTL cycles</strong> whenever unresolved
    complexities or ambiguities arose during investigation of the public literature. Through these conversations we
    developed not just technical knowledge, but a <strong>deep industrial understanding</strong> of precision
    fermentation, strain engineering, protein manufacturing in yeast, and the <strong>regulatory and investment
    landscape</strong> of alternative proteins.
    <br><br>
    This became our team’s unique edge — and the key conversations that shaped us are highlighted in the timeline
    below, as they fundamentally redirected our project at critical moments.
    <br><br><br>
    Use the <i>quick links</i> below to explore each phase of our journey:
  </p>

  <div class="spacer5"></div>

  <div>
    <p style="text-align: center;">
      <a class="text-glitch" href="#project-planning"><strong>IDEATION</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon" class="icon-separator">
      <a class="text-glitch" href="#research-and-experimentation"><strong>RESEARCH</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon" class="icon-separator">
      <a class="text-glitch" href="#downstream-and-implementation"><strong>DOWNSTREAM PROCESSING</strong></a>
      <img src="https://static.igem.wiki/teams/5916/assets/icons/arrow3.webp" alt="separator icon" class="icon-separator">
      <a class="text-glitch" href="#entrepreneurship-and-translation"><strong>FINANCE / FUNDING</strong></a>
    </p>
  </div>
</div>

<div class="spacer5"></div>

<div class="page-section width-75">
  <p style="text-align: left;">
    Or use the <i>timeline</i> below to follow our journey chronologically:
  </p>
  <!-- SECTION START: People Timeline Navigation -->
<div class="people-timeline">
  <div class="timeline-line"></div>
  <div class="timeline-row timeline-row-top">
    <div class="timeline-item no-icon"><a href="#lisa-neidhardt-oliver-konzock">
        <div class="timeline-name">Dr. Lisa Neidhardt<br>& Dr. Oliver Konzock</div> <!-- if you want exact spelling fix: Neidhardt is correct; your current text shows Niedhardt -->
      </a></div>
    <div class="timeline-item"><a href="#jason-yu">
        <div class="timeline-name"><strong>Dr. Jason Yu</strong></div>
        <div class="timeline-icon"><img class="tilt-effect"
            src="https://static.igem.wiki/teams/5916/assets/images/team/jason.webp" alt="Dr. Jason Yu"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#martin-carballo-pacheco">
        <div class="timeline-name">Martin Carballo Pacheco</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#ruben-perez-carrasco">
        <div class="timeline-name">Dr. Ruben Perez-Carrasco</div>
      </a></div>
    <div class="timeline-item"><a href="#mark-warner">
        <div class="timeline-name"><strong>Mark Warner</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/mark1.webp"
            alt="Mark Warner"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#noah-sprent">
        <div class="timeline-name">Dr. Noah Sprent</div>
      </a></div>
    <div class="timeline-item"><a href="#brigitte-gasser">
        <div class="timeline-name"><strong>Dr. Brigitte Gasser</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/brigitte1.webp"
            alt="Dr. Bridgitte Gasser"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#victoria-faber">
        <div class="timeline-name">Victoria Faber</div>
      </a></div>
    <div class="timeline-item"><a href="#nelli-morgulchik">
        <div class="timeline-name"><strong>Nelli Morgulchik</strong></div>
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/nelli1.webp"
            alt="Nelli Morgulchik"></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#hugh-bowen">
        <div class="timeline-name">Hugh Bowen</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#sara-holland">
        <div class="timeline-name">Sara Holland</div>
      </a></div>
  </div>
  <div class="timeline-row timeline-row-bottom">
    <div class="timeline-item"><a href="#alexander-van-de-steen">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/alex1.webp"
            alt="Dr. Alexander Van De Steen"></div>
        <div class="timeline-name"><strong>Dr. Alexander</strong><br><strong>Van De Steen</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#reka-tron">
        <div class="timeline-name">Reka Tron</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#matthieu-bultelle">
        <div class="timeline-name">Matthieu Bultelle</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#konstantin-pildish">
        <div class="timeline-name">Konstantin Pildish</div>
      </a></div>
    <div class="timeline-item"><a href="#martina-miotto">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martina.webp"
            alt="Martina Miotto"></div>
        <div class="timeline-name"><strong>Martina Miotto</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#sam-prudence">
        <div class="timeline-name">Dr. Sam Prudence</div>
      </a></div>
    <div class="timeline-item"><a href="#magnify-bio">
        <div class="timeline-icon"><img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/stealth.webp"
            alt="Magnify Bio"></div>
        <div class="timeline-name"><strong>Magnify Bio</strong></div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#olivia-brown">
        <div class="timeline-name">Olivia Brown</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#pedro-lovatt-garcia">
        <div class="timeline-name">Pedro Lovatt Garcia</div>
      </a></div>
    <div class="timeline-item no-icon"><a href="#katie-moruzzi">
        <div class="timeline-name">Katie Moruzzi</div>
      </a></div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: People Timeline Navigation -->

<!-- OPEN the main timeline wrapper (was missing in v4) -->
<div class="snake-timeline">

  <!-- PHASE: Project Planning -->
  <div class="timeline-section-header" id="project-planning">
    <h3 class="tagline-subline">Project Planning</h3>
  </div>

<div class="spacer5"></div>
<!-- SECTION END: Top (Hero + Intro + Navigation) -->
<!-- SECTION START: Lisa Neidhardt & Oliver Konzock -->
 <!-- PHASE ANCHOR -->
<div id="project-planning"></div>
<div id="lisa-neidhardt-oliver-konzock" class="two-column-container timeline-event">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center; margin-bottom: 0;">
        <span class="animate-text-scramble">Dr. Lisa Neidhardt &</span>
      </div>
      <div class="tagline-subline" style="text-align: center; margin-top: -1rem;">
        <span class="animate-text-scramble">Dr. Oliver Konzock</span>
      </div>

      <div class="two-column-container">
        <div class="column-left">
          <div class="image-aligner-left">
            <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/lisa.webp" style="max-width: 100%;">
          </div>
        </div>
        <div class="column-right">
          <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/oliver.webp" style="max-width: 100%;">
        </div>
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        Early in our ideation phase, we consulted with <strong>Dr. Lisa Neidhardt and Dr. Oliver Konzock</strong>, both
        postdoctoral researchers at the <strong>Rodrigo Ledesma-Amaro Lab</strong> with extensive experience in yeasts
        such as <em>Yarrowia lipolytica</em> and <em>Saccharomyces cerevisiae</em>.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left;">Aimed to identify the <strong>most suitable yeast chassis</strong> and framing for
            our <strong>alternative protein project</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Learned about <strong>regulatory challenges</strong> and the importance of
            <strong>GRAS status</strong> in accelerating approval.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Focused on <strong>cultivated meat</strong> and <strong>recombinant growth factor production</strong>
            as key cost barriers in the field.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Determined that <em>Y. lipolytica</em> was less efficient at secreting proteins and
            had slower DBTL cycles, leading to a pivot toward <em>K. phaffii</em>.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align:left;">
          We initially met with <strong>Dr. Lisa Neidhardt</strong>, a member of the <strong>Bezos Centre for Sustainable Protein</strong>
          and regional mentor for the <strong>Good Food Institute</strong>, to discuss how to frame our project so that it
          contributes meaningfully to the <strong>alternative protein field</strong>.
          <br><br>
          Dr. Neidhardt highlighted the inefficiencies of traditional food production — for instance, the 8:1 calorie
          conversion ratio for chicken — and shared examples of emerging sustainable protein ventures. She also drew
          attention to the <strong>regulatory burdens</strong> slowing down translation to market, emphasising that GRAS
          status can significantly accelerate approval.
          <br><br>
          Following this meeting, we decided to focus on <strong>cultivated meat</strong> — a promising but
          underexplored area of alternative proteins. Reports shared by Dr. Neidhardt identified <strong>recombinant growth factors</strong>
          as one of the main cost drivers in the field, guiding us to position our project as a solution to this
          specific bottleneck.
        </p>

        <div class="spacer"></div>

        <p style="text-align:left;">
          Our follow-up discussion with <strong>Dr. Oliver Konzock</strong> centred on microbial chassis selection.  
          He explained the design and transformation cycle of <em>Y. lipolytica</em>, noting that its slow growth and
          non-standard DNA parts would make it impractical within the iGEM timeline, where a single DBTL cycle could take
          over a month.  
          Drawing on his experience as a two-time iGEM team leader at TU Braunschweig, he advised us to
          design a project that would remain <strong>communicable to the public and feasible for students</strong>.
          <br><br>
          Following his advice, we explored <em>Komagataella phaffii</em> as a faster-cycling yeast with higher
          secretion efficiency and more industrial relevance.  
          <strong>Dr. Neidhardt and Dr. Konzock’s guidance</strong> gave us the clarity to focus our wet-lab strategy on
          a chassis that would remain time-resilient and scalable.  
          Both continued as project advisors throughout our journey.
        </p>
        <div class="collapsible-close">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Lisa Neidhardt & Oliver Konzock -->
<!-- SECTION START: Dr. Alexander Van de Steen -->
<div id="alexander-van-de-steen" class="two-column-container timeline-event">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Alexander Van de Steen</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/alex1.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        Continuing our chassis selection process, we met with <strong>Dr. Alex Van de Steen</strong>, a
        <strong>postdoctoral researcher at the Bezos Centre for Sustainable Protein</strong> with expertise in
        <em>K. phaffii</em>.  
        This consultation aimed to clarify the <strong>practical timelines</strong> of <em>K. phaffii</em> engineering
        and determine whether it was the most strategic choice for our goals.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left;">Wanted to assess the <strong>practicality</strong> and
            <strong>strategic fit</strong> of <em>K. phaffii</em> as our project's chassis.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Learned that <em>K. phaffii</em> can achieve
            <strong>sub-month transformation cycles</strong> and offers <strong>high secretion capacity</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Confirmed its advantages for <strong>high-yield protein production</strong>
            aligned with our project goals.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Received <strong>validation</strong> and continued
            <strong>advisory support</strong> on experimental design and troubleshooting throughout the project.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          <strong>Dr. Van de Steen</strong> confirmed that <em>K. phaffii</em> transformation cycles can be compressed
          to under one month and, with optimisation, may approach the speed of <em>S. cerevisiae</em>.  
          However, he cautioned that unless our project specifically required <em>K. phaffii’s</em> strengths — such as
          <strong>high volumetric protein yield, absence of self-inhibition, or superior secretion capacity and chaperone
          availability</strong> — there would be no inherent advantage over faster or better-characterised organisms like
          <em>E. coli</em>.
          <br><br>
          Because our goal was to leverage <strong>K. phaffii’s secretion abilities for growth factor production</strong>,
          this conversation gave us the <strong>confidence to move forward with it as our chassis of choice</strong>.
          We later consulted Dr. Van de Steen again for feedback on our final experimental plan before ordering parts,
          where he referred us to <strong>Dr. Jason Yu</strong> regarding CRISPR design specifics but approved our cloning
          and analytical methods.  
          He continued advising us throughout troubleshooting in the shared laboratory spaces.
        </p>
        <div class="collapsible-close">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Alexander Van de Steen -->
<div class="timeline-section-header header-grey" id="research-and-experimentation">
  <div class="tagline-subline"><span>Research and Experimentation</span></div>
</div>
<div class="timeline-section-header header-grey" id="pichia-engineering">
  <div class="tagline-subline"><span>Pichia Engineering</span></div>
</div>
<!-- SECTION START: Dr. Brigitte Gasser -->
<div id="brigitte-gasser" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Brigitte Gasser</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/brigitte1.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        <strong>Dr. Brigitte Gasser</strong> is an Associate Professor for Microbial Systems Biotechnology and
        leader of Sustainable Production at the <strong>Austrian Centre of Industrial Biotechnology (ACIB)</strong>
        at BOKU University in Vienna.  
        Her expertise spans systems and synthetic biology for <em>K. phaffii</em> engineering, holding over
        <strong>20 patent families</strong> and serving on the editorial board of *FEMS Yeast Research*.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Aimed to get insights from a <strong>leading academic</strong> in
            <strong>industrial <em>K. phaffii</em> design</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Learned about <strong>differing academic vs. industrial views</strong>
            on mannan impurity relevance.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Decided <strong>against focusing on folding and ER-stress
              pathways</strong> due to non-generalizable impact.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Identified <strong>new downstream stakeholders</strong> in
            pharmaceutical biomanufacturing.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          We reached out to <strong>Dr. Gasser</strong> to gain an expert perspective on the current frontiers of
          <em>K. phaffii</em> chassis improvement — particularly in <strong>metabolic engineering,
          folding, and stress-response pathways</strong>.  
          <br><br>
          When asked about industry concerns over <strong>polymannose contamination</strong> in high-cell-density
          cultures, she noted that this was **not yet a major issue raised by industry**, although academic work has
          begun exploring its effect on yield and purification. She confirmed that streamlining sugar metabolism remains
          a promising route for improving titres.
          <br><br>
          Dr. Gasser also pointed out bottlenecks in producing heterologous proteins with multiple disulfide bonds,
          which can lead to <strong>ER-associated degradation or cell lysis</strong>. While overexpressing UPR proteins
          or chaperones can sometimes mitigate this, she explained that such strategies rely on combinatorial tuning and
          are rarely generalisable — leading us to deprioritise this avenue for iGEM’s scope.
          <br><br>
          On fermentation, she described how most industrial <em>K. phaffii</em> processes still rely on
          <strong>fed-batch methanol systems</strong> but that continuous fermentation using other feedstocks such as
          glucose is gaining attention. Although we could not test this experimentally, this insight informed our
          understanding of future <em>K. phaffii</em> bioprocess design directions.
          <br><br>
          Finally, Dr. Gasser mentioned emerging initiatives — such as grants targeting “$10 per kg” monoclonal antibody
          production from the Bill & Melinda Gates Foundation — that motivate cost reduction for complex
          protein production. This highlighted new potential beneficiaries of a more efficient <em>K. phaffii</em>
          chassis, beyond cultivated meat applications.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Brigitte Gasser -->
<!-- SECTION START: Dr. Sam Prudence -->
<div id="sam-prudence" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Sam Prudence</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/sam.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        <strong>Dr. Samuel Prudence</strong> is a Senior Research Fellow at the <strong>University of Canterbury</strong>
        in New Zealand. His work focuses on <strong>strain engineering of filamentous fungi</strong> for reducing
        methane emissions in ruminants, and he formerly served as Senior Scientist at <strong>Better Dairy</strong>, a
        precision fermentation company based in London.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Aimed to understand <strong>industrial yeast strain engineering
              challenges</strong> and realistic bottlenecks.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Confirmed <strong>industrial advantages</strong> of
            <em>K. phaffii</em> compared to other hosts.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Identified a <strong>restrictive patent landscape</strong> around
            yeast strain engineering.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Began advocating for <strong>open-source strain development</strong>
            to empower early-stage biotech innovation.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          We reached out to <strong>Dr. Prudence</strong> during his time at <strong>Better Dairy</strong> to better
          understand the challenges faced by startups developing commercial yeast strains under industrial constraints.
          <br><br>
          He emphasised a key obstacle: the <strong>crowded and restrictive IP landscape</strong> surrounding
          industrially useful yeast strains.  
          Many strains are protected by commercial licences held by large contract manufacturers, leaving startups that
          cannot afford licensing at a disadvantage.  
          This reinforced our later interest in **open-license strain development** and transparency in strain
          characterisation.
          <br><br>
          Dr. Prudence also discussed the **tension between venture capital timelines and scientific progress**.
          Companies are often expected to generate revenue while still scaling up operations, widening what he called
          the “valley of death” for biotech ventures.  
          He advised that the best strategy is to develop **revenue-generating components within a university context**
          before spinning out — a model we found particularly relevant to iGEM teams.
          <br><br>
          We also discussed **downstream processing bottlenecks**, which he identified as a major scaling barrier in the
          UK due to a lack of affordable, food-grade biomanufacturing facilities.  
          This echoed concerns from later consultations, showing that even well-engineered strains cannot succeed
          without appropriate industrial infrastructure.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Sam Prudence -->
<!-- SECTION START: Reka Tron -->
<div id="reka-tron" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Reka Tron</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/reka1.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        Very early on in our journey, we met with <strong>Reka Tron</strong>, <strong>former COO at Multus Media</strong> and a
        <strong>specialist in <em>K. phaffii</em> engineering and growth factor production</strong>.  
        With a strong background in alternative protein media solutions and cultivated meat strategy, her input helped us
        understand both the <strong>technical and industry perception</strong> challenges shaping our field.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:#ffffff;">Wanted to figure out the <strong>cultivated meat market’s
              biggest needs</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Settled on producing <strong>FGF2, IGF, EGF, and HGF</strong> and
            developing strategies to <strong>express</strong> them efficiently.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Adopted education strategies that better highlight
            <strong>industry and public perception challenges</strong> of cultivated meat.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Decided against <strong>protein engineering of growth factors</strong>
            as it would not add meaningful impact within our timeline.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Our focus was understanding the <strong>key challenges in industrial <em>K. phaffii</em> applications</strong> and
          the broader landscape of cultivated meat media companies.  
          <br><br>
          Reka shared her experience overseeing growth factor production pipelines and validated our emphasis on
          <strong>IGF-1, EGF, and HGF</strong> as high-demand targets in cultivated meat.  
          She noted that while <strong>IGF-1 and EGF</strong> are smaller and easier to express, <strong>HGF</strong> poses
          significant difficulties due to its complex multi-chain structure and susceptibility to cleavage.  
          She recommended we include <strong>FGF2</strong> as an easier, more stable target with strong industrial
          relevance — advice that shaped our final experimental design.
          <br><br>
          Reka also discussed her previous company’s work in <strong>engineering growth factors for improved
          dose-response properties</strong>, showing us an alternate approach to reducing production costs.  
          However, given our focus on <strong>strain engineering and bioprocess design</strong>, we decided not to pursue
          protein modification within the iGEM timeframe.
          <br><br>
          The second part of our conversation turned to <strong>industry and public perception</strong>.  
          Reka explained that attention within the sector is shifting towards <strong>media composition and sustainability</strong>,
          with increasing interest in waste-derived carbon sources.  
          At the same time, she noted a growing public fatigue and investor caution towards alternative proteins — a
          realism that encouraged us to tailor our outreach and educational materials to address these perceptions more
          directly.
          <br><br>
          Overall, her insights helped us balance ambition with practicality, refine our target protein list, and
          develop a grounded communication strategy aligned with the current state of the industry.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Reka Tron -->
<!-- SECTION START: Dr. Jason Yu -->
 <!-- PHASE ANCHOR -->
<div id="research-and-experimentation"></div>
<div id="jason-yu" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Jason Yu</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/assets/images/team/jason.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        <strong>Dr. Jason Yu</strong> is a researcher in the <strong>Polizzi Lab, Department of Chemical Engineering</strong>
        at Imperial College London. His work focuses on <strong>CRISPR-Cas9 engineering to modify flocculation behaviour
        in <em>K. phaffii</em></strong> — a topic directly relevant to cultivated meat bioprocessing.  
        His guidance played a crucial role in defining our <strong>engineering strategy, transformation workflow,</strong> and
        <strong>troubleshooting pipeline</strong>.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:#ffffff;">Aimed to validate <strong>CRISPR-Cas9 design and workflow</strong>
            for <em>K. phaffii</em> strain engineering.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Decided against <strong>multiplexed edits</strong> due to metabolic
            and <strong>cell viability concerns</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Refined our approach to <strong>gene insertion</strong> using
            <strong>inducible promoters</strong> and targeted sgRNAs.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Integrated <strong>electroporation</strong> into our workflow,
            significantly improving transformation success rates.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          We reached out to <strong>Dr. Yu</strong> to refine our CRISPR-Cas9 design strategy for
          <em>K. phaffii</em> and ensure our approach was viable within iGEM constraints.  
          At this stage, we had identified gene targets and designed initial sgRNAs with the goal of modifying Kozak
          sequences to tune expression levels.  
          After reviewing our plan, Dr. Yu advised us to **abandon multiplexed editing**, which could cause metabolic
          strain and reduce viability, and instead focus on **single edits with clear functional endpoints**.
          <br><br>
          Through multiple discussions, we pivoted toward **Cas9-mediated gene insertions under inducible promoters**
          rather than promoter modifications.  
          Dr. Yu also introduced us to a **ΔKu70 strain of <em>K. phaffii</em>**, which improves homologous recombination
          efficiency, and he kindly provided us with aliquots of this strain for our experiments.
          <br><br>
          One of the most impactful contributions was his recommendation to incorporate **electroporation** into our
          transformation workflow — a method none of us had previously used — which ultimately enabled successful DNA
          delivery and stable integration.  
          He also provided insights on **primer design** for integration verification and explained how to
          interpret ambiguous gel results for CRISPR construct validation.
          <br><br>
          Dr. Yu’s ongoing mentorship shaped both our wet lab execution and our understanding of how to translate
          genetic edits into industrially meaningful outcomes.  
          He continued advising us throughout the summer and was formally onboarded as a project advisor.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Jason Yu -->
<!-- SECTION START: Brandon Ma -->
<div id="brandon-ma" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Brandon Ma</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/brandon1.webp" style="max-width: 80%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We held two in-depth consultations with <strong>Brandon Ma</strong>, <strong>Senior Scientist and Co-Founder of Multus Media</strong>,
        to refine both our technical execution and overall project strategy in <em>K. phaffii</em> engineering.
        His experience developing industrial-scale precision-fermentation platforms provided an invaluable reality check
        on the feasibility and direction of our wet-lab work.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:#ffffff;">Consulted on our <strong><em>K. phaffii</em> engineering strategy</strong> and its
            industrial <strong>feasibility</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Focused on validating <strong>reduced impurity production</strong>
            over immediate growth-factor purification.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Added <strong>FGF2</strong> to our research design, prioritising
            smaller proteins with <strong>simpler post-translational modifications</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:#ffffff;">Implemented <strong>quick <em>K. phaffii</em> monitoring steps</strong>
            to confirm experimental success efficiently.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          From his time pivoting away from <em>K. phaffii</em>-based growth-factor production, <strong>Brandon Ma</strong>
          shared first-hand insight into the challenges of an <strong>overcrowded IP landscape</strong>,
          <strong>CMO dependencies</strong>, and complex patent restrictions.
          He encouraged us to frame our proof-of-concept around
          <strong>reducing impurity production</strong> rather than pursuing full purification within the iGEM timeframe,
          aligning our objectives with realistic industrial outcomes.
          <br><br>
          He also gave practical guidance for working with <em>K. phaffii</em>: beginning with the <strong>wild-type CBS 7435 strain</strong>,
          using small DNA constructs (~80 ng), and validating >100 clones via dot-blot screens.
          Although infeasible for our scale, this insight clarified the standards of industrial workflows.
          Brandon also shared troubleshooting advice — from monitoring pellet colour and smell to
          <strong>dual-antibiotic selection</strong> for contamination control.
          <br><br>
          For CRISPR design, he advised manually verifying primer targets against the <em>K. phaffii</em> genome via NCBI,
          ordering redundant primer sets, and sequencing ambiguous bands for validation.
          He recommended software tools for codon optimisation and suggested comparing multiple optimised variants to
          assess expression efficiency.
          <br><br>
          In terms of targets, he advised prioritising <strong>EGF and IGF</strong> because of their higher stability
          and flagged <strong>HGF</strong> as particularly unstable due to its multi-chain structure.
          He proposed <strong>FGF2</strong> as a more reliable and scalable protein, which we subsequently added as a
          verification target for our recombinant-protein workflow.
          <br><br>
          Overall, Brandon’s consultation reframed our technical aims around practicality,
          helping us design experiments that could translate directly into industrial relevance.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Brandon Ma -->
 <div class="timeline-section-header header-grey" id="pichia-engineering">
  <div class="tagline-subline"><span>Pichia Engineering</span></div>
</div>
<!-- SECTION START: Dr. Ruben Perez-Carrasco -->
<div id="ruben-perez-carrasco" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Ruben Perez-Carrasco</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/ruben.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We consulted <strong>Dr. Ruben Perez-Carrasco</strong>, <strong>Associate Professor in Theoretical Systems Biology</strong>
        and head of the Perez-Carrasco Lab at Imperial College London, to refine our computational approach to
        <strong>Bayesian optimisation</strong> for pathway engineering.  
        Our discussions focused on handling <strong>biological noise</strong> in synthetic biology data and validating our
        model pipeline for experimental integration.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Aimed to explore <strong>Bayesian optimisation</strong> methods and
            techniques for managing <strong>biological noise</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Validated the use of <strong>synthetic datasets</strong> with
            <strong>simple ODE outputs</strong> and <strong>Gaussian noise</strong> for model testing.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Adopted <strong>Bayesian inference tools (PyMC)</strong> for
            experimental variable integration.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Redesigned dry-lab validation to ensure <strong>biological accuracy
              and reproducibility</strong> in model predictions.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Our consultation with <strong>Dr. Perez-Carrasco</strong> focused on adapting Bayesian optimisation for use in
          biological systems — specifically, the challenges of fitting noisy wet-lab data to dynamic models.
          He recommended that we first create a <strong>synthetic dataset</strong> using simplified ODE systems with
          Gaussian noise before introducing heteroscedastic variation, ensuring that our optimisation function behaved
          as expected under controlled noise.
          <br><br>
          He highlighted the use of <strong>PyMC</strong> as a powerful tool for Bayesian inference, allowing us to
          extract experimentally derived parameters and feed them back into the model iteratively.  
          This approach, he explained, would strengthen the connection between simulation and experiment — an essential
          step for data-driven model refinement.
          <br><br>
          Additionally, he reminded us that **biological noise must be contextualised**: fluctuations can arise not only
          from measurement error but also from population heterogeneity or metabolic state changes.  
          To ensure biological validity, he advised maintaining cultures strictly within the log-growth phase and
          avoiding over-crowding, since that would shift metabolic profiles and confound results.
          <br><br>
          Finally, Dr. Perez-Carrasco provided key literature references on noise modelling and suggested using
          small-scale test cases to benchmark our pipeline before applying it to real data — an approach that later
          defined the early validation stage of our dry-lab workflow.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Ruben Perez-Carrasco -->
 <!-- BEGIN REPLACE: #matthieu-bultelle (under Research and Experimentation) -->
<div id="matthieu-bultelle" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
  <div class="timeline-dot"></div>
  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Matthieu Bultelle</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/matthieu.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>
  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;"><strong>Imperial College London researcher</strong> in lab automation and synthetic biology (Kitney Lab). We consulted Dr. Bultelle for his expertise in <strong>replicable engineering-biology workflows</strong> and <strong>automation</strong>. His advice was vital for setting early goals and structuring our <strong>Bayesian optimisation</strong> campaign for astaxanthin bioproduction experiments.</p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Sought suggestions for <strong>improvement of optimisation validation</strong> experiments.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;"><strong>Focused specific varying properties</strong> to reduce complexity.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Adjusted <strong>inducer handling</strong> for better <strong>accuracy</strong> and <strong>comparability</strong> across trials.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Simplified <strong>workflows</strong> and prioritised <strong>proof-of-concept validation</strong>.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">His initial advice centred on <strong>repeatability</strong> and managing <strong>experimental variance</strong>. We were encouraged to vary <strong>stimulus/environmental properties</strong> while avoiding introducing <strong>genetic variation</strong> (higher time/resource cost). He flagged <strong>inducer concentration accuracy</strong> as a common issue with small volumes, prompting us to use <strong>larger dispensed volumes</strong> and <strong>bulk preparation</strong> to minimise confounders and improve cross-trial comparability.</p>
        <p style="text-align: left;">Finally, we simplified the experimental design, leaning on established techniques and straightforward workflows. On short timelines, he advised against designing our own OpenTron automation protocol, so we kept focus on a solid <strong>proof-of-concept</strong> experiment.</p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>
<!-- END REPLACE: #matthieu-bultelle -->
<!-- SECTION START: Dr. Martin Carballo Pacheco -->
<div id="martin-carballo-pacheco" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Martin Carballo Pacheco</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martin.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We met with <strong>Dr. Martin Carballo Pacheco</strong>, <strong>Senior Scientist at Hoxton Farms</strong>,
        a biotechnology company pioneering cultivated pork fat production.  
        His expertise in <strong>computational biology and chemistry</strong> provided vital insight into the
        <strong>technical bottlenecks</strong> and <strong>market realities</strong> of cultivated meat manufacturing.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Aimed to discuss the <strong>market relevance</strong> of our growth-factor platform.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Validated assumptions on <strong>bottlenecks in growth-factor
              supply</strong> and their impact on cultivated meat scalability.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Confirmed integration of <strong>Bayesian optimisation</strong> into
            modelling workflows for rapid testing.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Reinforced the <strong>techno-economic importance</strong> of growth
            factors in cultured-meat media.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Our team consulted <strong>Dr. Carballo Pacheco</strong> to understand the industrial and economic context of
          growth-factor production.  
          As a senior scientist at <strong>Hoxton Farms</strong>, a company specialising in cultivated pork fat, he
          offered first-hand insight into the current state of the field and the barriers preventing commercial scaling.
          <br><br>
          He explained that while <strong>growth factors are available on the milligram scale</strong>, few suppliers can
          provide them affordably at the kilogram scale required for food-grade manufacturing.
          This limitation represents one of the most significant unsolved challenges in the cultivated meat sector.
          He pointed us toward a <a href="https://gfi.org/wp-content/uploads/2021/11/Cultivated-meat-media-and-growth-factor-trends-2020.pdf"
            target="_blank" style="color:#bdf968;">Good Food Institute report</a>
          showing that growth factors can contribute up to <strong>90% of media cost</strong> — validating the
          importance of our project focus.
          <br><br>
          We also discussed how <strong>Bayesian optimisation</strong> could streamline process development.
          Martin shared that Hoxton Farms uses similar computational tools for small-scale media testing before scaling
          to pilot systems, confirming the real-world applicability of our dry-lab approach.
          He highlighted the use of <strong>transfer learning</strong> to minimise experimental footprint and speed up
          parameter refinement — an insight we later implemented in our modelling workflow.
          <br><br>
          Finally, Martin emphasised the importance of <strong>partnerships between academic and industrial groups</strong>
          to validate practical applications, noting that collaboration is key to bridging the current market gap in
          affordable, food-grade growth factors.  
          He later joined us as a guest speaker at our <strong>Mini Jamboree</strong>, where he presented Hoxton Farms’
          technology and gave feedback on our project pitch.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Martin Carballo Pacheco -->
 <div class="timeline-section-header" id="downstream-and-implementation">
  <div class="tagline-subline"><span>Downstream &amp; Implementation</span></div>
</div>
<div class="timeline-section-header" id="industry-overall">
  <div class="tagline-subline"><span>Industry Overall</span></div>
</div>
<!-- SECTION START: Konstantin Pildish -->
 <!-- PHASE ANCHOR -->
<div id="downstream-and-implementation"></div>
<div id="konstantin-pildish" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Konstantin Pildish</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/konstantin.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We met with <strong>Konstantin Pildish</strong>, <strong>Global Purification Technologist at Lonza</strong>, to
        refine our <strong>protein purification strategy</strong> and ensure our pipeline aligned with real-world
        bioprocessing practices.  
        His expertise in downstream development was critical to validating our use of <em>K. phaffii</em> for
        food-grade protein production.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Consulted to refine our <strong>protein purification strategy</strong>
            for <em>K. phaffii</em> growth-factor production.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Confirmed <strong><em>K. phaffii</em>’s suitability</strong> for
            producing food-grade recombinant proteins.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Validated our choice of <strong>His-tag affinity chromatography</strong>
            at lab scale and recommended <strong>reverse-phase chromatography</strong> for pilot setups.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Provided realistic yield expectations and <strong>scalable process
              insights</strong> for bioreactor-level purification.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Our meeting with <strong>Konstantin Pildish</strong> at <strong>Lonza</strong> was aimed at grounding our
          purification design in industrial reality.  
          He confirmed that <em>K. phaffii</em> is an ideal chassis for producing <strong>food-grade proteins</strong>
          that require complex folding but not humanised glycosylation, making it particularly suitable for our
          cultivated-meat applications.
          <br><br>
          He noted that most growth factors fall below 1000 amino acids, simplifying purification steps and reducing
          sterility requirements compared to pharmaceutical-grade production.  
          This validated our approach of focusing on **functional yield over therapeutic precision**.
          <br><br>
          Konstantin confirmed that our use of <strong>His-tag affinity chromatography</strong> was appropriate for small
          lab-scale runs, allowing easy quantification and quality control.  
          However, for scale-up, he recommended switching to **ultrafiltration or microfiltration** for bulk separation
          and **reverse-phase chromatography** for polishing — a lower-cost, food-safe method used at industrial levels.
          <br><br>
          He also provided realistic expectations for achievable titres in <em>K. phaffii</em>, estimating
          <strong>~0.5 g/L yields</strong> under optimised fed-batch conditions.  
          Finally, Konstantin discussed bioreactor scalability, recommending <strong>1000L single-use systems</strong>
          operating under **ISO 7 food-grade standards**, which reduce sterility and quality-assurance costs compared to
          pharma-grade environments.
          <br><br>
          His advice directly informed the downstream design we featured in our final bioprocess flow diagram and helped
          us set achievable experimental benchmarks.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Konstantin Pildish -->
 <!-- BEGIN REPLACE: #magnify-bio (under Downstream & Implementation / Industry Overall) -->
<div id="magnify-bio" class="two-column-container timeline-event">
  <div class="timeline-dot"></div>
  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Magnify Bio</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/magnify.webp" style="max-width: 40%;">
      </div>
    </div>
  </div>
  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">We connected with <strong>Blake Byrne</strong> (CEO; ex-GFI tech analyst) via <strong>Mark Warner</strong> (Liberation Bioindustries) for their <strong>cutting-edge downstream recovery</strong> expertise. We also spoke with Magnify Bio’s CTO, <strong>Dr. Christian Schuster</strong>.</p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left;">Aimed to assess <strong>downstream processing challenges</strong> in <em>K. phaffii</em>.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Processing costs showed <strong>the potential financial savings</strong> our solution could deliver.</li>
          <div class="spacer"></div>
          <li style="text-align:left;"><strong>Polysaccharide contamination</strong> confirmed to affect purification feasibility.</li>
          <div class="spacer"></div>
          <li style="text-align:left;"><strong>Gaps identified</strong> in stakeholder mapping, prompting further interviews.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">We sought their assessment of <strong>downstream issues</strong> in <em>K. phaffii</em>. Dr. Schuster confirmed that efforts to improve processing are <strong>organised by target-protein properties</strong>. <strong>Polysaccharide contamination</strong> in supernatant can be significant — especially when contaminants share a similar <strong>mass band</strong> or cannot be separated via <strong>ion exchange</strong>.</p>
        <div class="spacer"></div>
        <p style="text-align: left;">This <strong>validated removing such impurities</strong>, though it is not a magic bullet: protein properties (mass/charge) can negate impurity importance by enabling other recovery techniques.</p>
        <div class="spacer"></div>
        <p style="text-align: left;">According to Dr. Schuster, <strong>purification costs</strong> in broader biomanufacturing typically range <strong>20–80€ per kg</strong> at average purity; costs rise sharply with higher lysis/contaminants as <strong>additional unit operations</strong> become necessary. Higher expression is not always cheaper — it can exacerbate downstream costs and disproportionately affect novel bioeconomy players seeking price parity.</p>
        <div class="spacer"></div>
        <p style="text-align: left;">This also exposed a gap in our stakeholder mapping: <strong>food proteins</strong> (e.g., recombinant casein) may face similar purification challenges as growth factors while needing <strong>even lower prices</strong> to compete with dairy. We raised this with Dr. Van de Steen, who pursues <strong>recombinant milk proteins</strong> scale-up, where recovery costs can make or break viability.</p>
        <div class="collapsible-close">Close</div>
      </div>
    </div>
  </div>
</div>
<!-- END REPLACE: #magnify-bio -->
<!-- SECTION START: Professor Cleo Kontoravdi -->
<div id="cleo-kontoravdi" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Professor Cleo Kontoravdi</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/cleo.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We recognised a critical gap in our expertise — none of us had experience in translating bench-scale synthetic
        biology into <strong>manufacturable bioprocesses</strong>.  
        Our first consultation to address this was with <strong>Professor Cleo Kontoravdi</strong>, an expert in
        <strong>Process and Biological Systems Engineering</strong>, whose guidance fundamentally reshaped the trajectory
        of our project.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Wanted to bridge our gap in <strong>translating bench-scale biology</strong>
            into scalable bioprocess design.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Learned that <strong>molecular biology decisions</strong> directly
            impact every stage of downstream processing.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Reframed <strong>secreted vs. intracellular expression</strong> as a
            determinant of scalability and purification strategy.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Shifted our design philosophy to <strong>prioritise commercial
              viability</strong> early in strain selection.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Professor Kontoravdi introduced us to a principle that became central to our design philosophy:
          <strong>decisions made at the molecular biology stage cascade through the entire bioprocess</strong>.
          She explained that we must consider product classification (food-grade vs. pharmaceutical),
          cost per unit output, and regulatory pathways from the outset — not as late-stage adjustments.
          <br><br>
          Most pivotally, she reframed how we viewed <strong>secreted vs. intracellular expression</strong> — what we
          initially thought was a molecular optimisation detail actually dictated our entire downstream processing
          strategy.  
          This choice would affect everything from purification complexity and yield recovery to scalability and
          equipment requirements.
          <br><br>
          Her insights marked a turning point in our planning: **scalability became a core design criterion**, rather
          than a downstream concern.  
          From that moment, our experimental decisions began reflecting a “bench-to-bioreactor” mindset — designing not
          just for proof of concept, but for industrial translation.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Professor Cleo Kontoravdi -->
  <div class="timeline-section-header header-grey" id="entrepreneurship-and-translation">
  <div class="tagline-subline"><span>Entrepreneurship and Translation </span></div>
</div>
<div class="timeline-section-header header-grey" id="vision-and-mission">
  <div class="tagline-subline"><span>Vision and Mission</span></div>
</div>
<!-- SECTION START: Martina Miotto -->
<div id="martina-miotto" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Martina Miotto</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/martina.webp" style="max-width: 80%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        <strong>Dr. Martina Miotto</strong> advised us on translating lab results into product-ready outputs,
        emphasising how to scope technical goals against <strong>manufacturability</strong> and <strong>food-grade QA</strong> constraints.
      </p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left;">Framed experiments around <strong>downstream feasibility</strong> rather than only yield.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Aligned <strong>QA/food-grade constraints</strong> with our strain-design choices.</li>
          <div class="spacer"></div>
          <li style="text-align:left;">Helped position outputs for <strong>realistic industrial uptake</strong>.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          We discussed practical constraints that often derail translation in food-biotech — costly purification,
          inconsistent QA expectations, and facility-grade decisions mismatched to application.
          Her feedback kept our focus on <strong>downstream simplicity</strong> as a driver of commercial viability,
          rather than assuming yield alone would determine success.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Martina Miotto -->
 <div class="timeline-section-header header-grey" id="business-strategy">
  <div class="tagline-subline"><span>Business Strategy</span></div>
</div>
<!-- SECTION START: Katie Moruzzi -->
 <!-- PHASE ANCHOR -->
<div id="entrepreneurship-and-translation"></div>
<div id="katie-moruzzi" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Katie Moruzzi</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/katie.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        As students developing a project in a patent-heavy industry, we faced uncertainty around how to bring our idea
        to market.  
        To clarify our options, we met with <strong>Katie Moruzzi</strong>, <strong>Imperial Expert-in-Residence</strong> and
        <strong>Associate at Briffa – Intellectual Property Lawyers</strong>.  
        Her guidance helped us navigate the <strong>legal, regulatory, and strategic frameworks</strong> that would shape
        our future IP decisions.
      </p>

      <p style="text-align: left;"><italic>Key Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Discussed <strong>legal and IP frameworks</strong> for plausible
            pathways toward company formation and protection.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Outlined a <strong>patent-filing timeline</strong> and strategy for
            verifying novelty and freedom-to-operate.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Evaluated trade-offs between <strong>patents</strong> and
            <strong>trade secrets</strong> for biotech startups.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Highlighted <strong>visa and incorporation barriers</strong> faced by
            international students.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          Katie explained the five main categories of intellectual-property protection — <strong>trademarks, copyright,
          registered designs, patents, and confidential know-how</strong> — and how each applies to early-stage biotech.
          <br><br>
          We discussed the tension between filing patents, which offer strong protection but require <strong>public
          disclosure</strong> and cost roughly <strong>£5 000 per country</strong>, and relying on <strong>trade
          secrets</strong>, which avoid disclosure but only work if the invention cannot be reverse-engineered.
          <br><br>
          Because <em>yeast engineering</em> is a heavily patented domain, she stressed the importance of
          <strong>prior-art searches</strong> and freedom-to-operate verification before filing.  
          She recommended checking potential names and logos through <strong>UK Companies House</strong> and
          <strong>IPO databases</strong>, and reaching out to <strong>SynBio-specialist patent attorneys</strong> — a step
          we began immediately after the meeting.
          <br><br>
          Finally, Katie clarified complications surrounding <strong>company formation for international students</strong>:
          visa restrictions often prevent immediate incorporation in the UK, risking fragmented ownership if IP is held
          individually.  
          She advised exploring alternative partnership or licensing structures to maintain unified rights until formal
          incorporation becomes possible.
          <br><br>
          This meeting equipped us with a clear understanding of how to protect our work and plan for future commercial
          steps responsibly and legally.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Katie Moruzzi -->
 <!-- BEGIN REPLACE: #sara-holland (under #ip) -->
<div id="sara-holland" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -1%;">
  <div class="timeline-dot"></div>
  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Sara Holland</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/sara.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>
  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">After our meeting with an IP lawyer, we continued our exploration of IP law by investigating patenting possibilities. We met with <strong>Sara Holland</strong>, Partner at <strong>Potter Clarkson</strong>, who specialises in biotechnology patents and has a track record of supporting iGEM teams.</p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Consulted on <strong>patentability criteria</strong> and <strong>timeline</strong> considering iGEM deliverables.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Researched the <strong>patentability and filing</strong> of our engineered constructs.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Confirmed <strong>feasibility of a short-term priority application</strong> to secure rights.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Ultimately <strong>reconfirmed our mission of advocating for open science.</strong></li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">She briefed us on patentability criteria, specifically how <strong>unique gene knockout combinations</strong> could be patentable if they produce <strong>unexpected synergistic effects</strong>. We also discussed patenting practices across different jurisdictions (US, UK, China). She recommended the <strong>European Patent Office</strong> as our primary venue because it is more favourable than the US due to narrower prior-art rules. However, the <strong>filing timeline</strong> was a major barrier: we would need a UK priority filing within days to avoid conflicts with iGEM deadlines. While <strong>minimal preliminary data</strong> would suffice for an initial filing, <strong>ownership uncertainty</strong> with Imperial complicated matters — Imperial could retain ownership and cover costs, disclaim ownership and leave costs to us, or negotiate shared ownership. After considering these factors, and staying aligned with our commitment to <strong>open science</strong>, we decided <strong>not to pursue patent protection</strong>, ensuring our work remains accessible to future iGEM teams while we focus on immediate project impact.</p>
        <div class="collapsible-close  collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>
<!-- END REPLACE: #sara-holland -->
 <div class="timeline-section-header header-grey" id="simulating-a-biotech-investor-pitch">
  <div class="tagline-subline"><span>Simulating a Biotech Investor Pitch</span></div>
</div>
 <!-- BEGIN REPLACE: #pedro-lovatt-garcia (under #simulating-a-biotech-investor-pitch) -->
<div id="pedro-lovatt-garcia" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>
  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Dr. Pedro Lovatt Garcia</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/pedro.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>
  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;"><strong>Dr. Pedro Lovatt Garcia</strong> is a <strong>student investor at Creator Fund</strong> who played a key role in refining both the <strong>strategic direction</strong> and <strong>communication</strong> of Growf’s pitch deck.</p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Aimed to trial-run our <strong>pitch deck</strong> and <strong>strategy</strong> in light of <strong>cultivated meat market challenges.</strong></li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Encouraged reframing the <em>K. phaffii</em> platform as a <strong>versatile tool beyond cultivated meat</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Shifted from specific cost figures to <strong>performance-based metrics</strong> (e.g., 3× improvements).</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Re-evaluated <strong>go-to-market</strong> with nearer-term applications (e.g., <strong>vaccine protein</strong> production).</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">With the cultivated meat industry facing significant post-2022 headwinds — rising interest rates, reduced venture funding, and more acquisitions — Pedro stressed adapting our narrative accordingly. He pushed us to <strong>broaden the platform framing</strong> to wider biomanufacturing use-cases (such as vaccine proteins) to reach investors with more immediate needs.</p>
        <p style="text-align: left;">We implemented deck changes: replacing exact prices with <strong>efficiency metrics</strong> (e.g., 3× gains), using the term <strong>“protein secretion”</strong> to reflect the platform’s breadth, and removing speculative cost projections in favour of <strong>evidence-backed efficiency data</strong> and potential savings. Go-to-market was refocused on better-timed verticals (e.g., vaccines), alongside <strong>target-customer definition</strong> and <strong>partner signalling</strong> to strengthen traction. As a near-term revenue option, he also suggested exploring <strong>strain IP</strong> sales before full GF pipelines.</p>
        <div class="collapsible-close  collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>
<!-- END REPLACE: #pedro-lovatt-garcia -->
 <div class="timeline-section-header header-grey" id="business-strategy">
  <div class="tagline-subline"><span>Business Strategy</span></div>
</div>
<!-- SECTION START: Victoria Faber -->
<div id="victoria-faber" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Victoria Faber</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/victoria.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We met with <strong>Victoria Faber</strong>, <strong>former Chief of Staff at Lightspeed Venture Partners</strong> and
        <strong>Angel Investor</strong>, to refine the <strong>strategic narrative and investor storytelling</strong> behind our pitch deck.  
        Her input was instrumental in transforming our presentation from an academic report into an investor-ready, high-impact story.
      </p>

      <p style="text-align: left;"><italic>Key Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Refined the <strong>strategic narrative</strong> and storytelling flow of our pitch.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Reframed the deck to follow a <strong>problem–solution–strategy</strong> structure.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Simplified technical language while maintaining <strong>scientific depth</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Enhanced <strong>visual pacing, whitespace,</strong> and clarity for investor engagement.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          With deep experience in strategic communications from her time at McKinsey and later at Lightspeed,
          <strong>Victoria Faber</strong> helped us elevate our pitch deck into a coherent, persuasive story that aligned
          with investor expectations.  
          <br><br>
          She guided us to structure the deck as a high-level narrative — beginning with a bold
          <strong>problem statement</strong>, followed by a visionary <strong>solution</strong> and a clearly defined
          <strong>strategic edge</strong>.  
          She emphasised that the flow of a pitch deck should engage emotionally before delving into technical depth.
          <br><br>
          We worked through the presentation slide by slide, simplifying dense technical descriptions into
          accessible language without sacrificing credibility.
          Victoria also stressed the importance of <strong>visual clarity</strong>, advising us to leverage whitespace,
          icons, and short thematic headlines to maintain reader attention.
          <br><br>
          Her detailed feedback led us to rebuild the deck with a <strong>more intuitive layout</strong> and
          <strong>clearer value proposition</strong>, replacing data-heavy visuals with strategic summaries that could
          be absorbed within seconds.
          <br><br>
          These changes not only elevated our investor materials but also shaped how we communicated our project across
          all outreach — from sponsor emails to conference presentations.
          <br><br>
          The two meetings with Victoria were transformative, marking our shift from a purely scientific mindset to one
          focused on <strong>storytelling, vision, and strategy</strong>.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Victoria Faber -->
<!-- SECTION START: Nelli Morgulchik -->
<div id="nelli-morgulchik" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Nelli Morgulchik</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/nelli.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        Following the refinement of our initial pitch narrative, we met with <strong>Nelli Morgulchik</strong>,
        <strong>biotech angel investor</strong> and <strong>co-founder of future.bio</strong> — a syndicate of investors and
        builders at the intersection of computation and biology.  
        Her experience as a former VC at <strong>Hummingbird Ventures</strong> provided us with practical, investor-side
        feedback on our deck, messaging, and outreach strategy.
      </p>

      <p style="text-align: left;"><italic>Key Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Reviewed our <strong>pitch deck</strong> and refined it for a
            <strong>biotech investor audience</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Recommended separating <strong>fundraising materials</strong> from the
            main deck to clarify our value proposition.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Advised adding a <strong>pricing slide</strong> and
            <strong>competitor analysis</strong> to demonstrate market advantage.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Encouraged clearer <strong>milestone breakdowns</strong> and
            <strong>performance indicators</strong> for investors.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          <strong>Nelli Morgulchik</strong> provided precise and pragmatic advice grounded in her years of experience as
          a venture capitalist and angel investor.  
          She recommended that we separate our <strong>pitch deck</strong> from any detailed
          <strong>fundraising documents</strong>, explaining that mixing them can blur messaging and weaken narrative
          focus.  
          Investors, she noted, want to see a clearly defined <strong>vision and differentiation</strong> before being
          asked to engage with numbers.
          <br><br>
          Nelli also encouraged us to incorporate a <strong>pricing and competitor analysis slide</strong> that
          benchmarks our solution against existing market offerings.  
          Demonstrating a quantifiable <strong>cost or performance advantage</strong> would make our project’s relevance
          far clearer to industry stakeholders.
          <br><br>
          She advised breaking our development plan into <strong>short-term milestones</strong> and a
          <strong>long-term roadmap</strong> supported by measurable KPIs, making it easier for investors to assess risk
          and progress.  
          This structure, she explained, reflects professional fundraising standards and inspires greater confidence in
          execution ability.
          <br><br>
          Beyond strategy, Nelli introduced us to <strong>industry contacts at Multus and Hoxton Farms</strong>, helping
          us secure further stakeholder consultations that strengthened our technical validation.
          <br><br>
          After implementing her feedback, we <strong>restructured our deck</strong>, added a detailed pricing analysis,
          clarified our differentiation, and reframed our narrative to centre more on <strong>cultivated meat
          scalability</strong> than on abstract innovation.  
          Her mentorship was key in aligning our communication with investor expectations and setting up a more focused
          fundraising approach.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Nelli Morgulchik -->
 <!-- SECTION START: Mark Warner -->
<div id="mark-warner" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Mark Warner</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/mark.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We consulted <strong>Mark Warner</strong>, <strong>CEO of Liberation Bioindustries</strong>, a leading
        large-scale contract manufacturer in Indiana, USA, to gain a grounded understanding of
        <strong>industrial-scale biomanufacturing challenges</strong> and identify how academic innovation translates
        into production realities.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Aimed to target <strong>industrial-scale biomanufacturing
              challenges</strong> and map realistic bottlenecks.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Learned about the <strong>perception gap</strong> between
            academic and industrial priorities.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Discovered that <strong>downstream purification</strong> often
            receives less attention than yield-focused strain engineering.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Understood that <strong>market coordination failure</strong> remains a
            central barrier to cultivated meat scale-up.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          <strong>Mark Warner</strong> brought decades of experience advising and leading manufacturing efforts across
          the alternative protein and food-biotech industries.  
          Our goal was to understand why promising academic approaches often fail to reach commercial scale.
          <br><br>
          He highlighted a striking disconnect between academia and industry — researchers often overestimate the impact
          of yield optimisation while overlooking <strong>downstream purification bottlenecks</strong>, which are more
          likely to limit industrial success.  
          Mark attributed this to a lack of incentive to share proprietary process data and the dominance of
          <strong>intellectual-property barriers</strong> that keep high-performing strains within private companies.
          <br><br>
          This conversation prompted us to acknowledge a major limitation in our own project:
          benchmarking strain performance quantitatively is difficult when the best data are proprietary.
          As a result, we redirected our focus toward addressing **impurities and secretion inefficiencies**, areas with
          room for open academic contribution.
          <br><br>
          Mark also discussed why many cultivated-meat companies struggle to scale: the field suffers from a
          <strong>“chicken-and-egg problem”</strong> — growth factors remain expensive due to lack of demand, while
          production companies hesitate to invest because of limited market activity.  
          He described this as a <strong>market coordination failure</strong> that hinders mutual growth.
          <br><br>
          Finally, he noted that most biomanufacturing facilities still follow <strong>pharmaceutical cleanroom
          standards</strong>, which are excessively costly for food-grade protein production.  
          This insight reinforced the relevance of our approach — developing yeast strains that simplify downstream
          processes could enable **cheaper, lower-grade facilities** to enter the market and unlock scale.
          <br><br>
          Based on Mark’s recommendation, we later contacted <strong>Blake Byrne</strong> and
          <strong>Dr. Christian Schuster</strong> at Magnify Bio, who provided further downstream process insights.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Mark Warner -->
<!-- SECTION START: Dr. Noah Sprent -->
<div id="noah-sprent" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Dr. Noah Sprent</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/noah.webp" style="max-width: 75%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        We reached out to <strong>Dr. Noah Sprent</strong>, <strong>Co-Founder of ChangeBio</strong>, a startup
        pioneering <em>K. phaffii</em>-based industrial protein manufacturing.  
        This consultation validated our <strong>engineering direction</strong> and led to a collaboration aimed at
        characterising an <strong>open-source <em>K. phaffii</em> strain</strong> for industrial use.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Aimed to validate our <strong><em>K. phaffii</em> engineering
              approach</strong> and explore open, commercially viable strain development.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Initiated a <strong>collaboration</strong> to characterise an
            open-source <em>K. phaffii</em> strain.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Designed an <strong>alternative non-CRISPR editing strategy</strong>
            to avoid licensing limitations.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Gained access to a <strong>2L bioreactor</strong> for industrially
            relevant fermentation validation.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          During planning for our Mini Jamboree, we contacted <strong>Dr. Sprent</strong> to discuss overlapping efforts
          around <strong>open biomanufacturing in <em>K. phaffii</em></strong>.  
          His startup, ChangeBio, focuses on creating open industrial protein-production systems — a perfect complement
          to our iGEM goals.
          <br><br>
          He validated our work targeting <strong>cell-wall and mannose pathway genes</strong>, highlighting that such
          optimisations remain underexplored despite the widespread industrial use of trHoc1 strains.
          Dr. Sprent confirmed that focusing on <strong>downstream efficiency</strong> is essential for improving
          scalability and cost-effectiveness.
          <br><br>
          We discussed a collaborative plan under his <strong>PhaffiiNet initiative</strong>, which aims to publish an
          <strong>open genome sequence and bioreactor data</strong> for <em>K. phaffii</em>, enabling public-domain
          strain access without commercial restrictions.  
          As part of this, he agreed to transfer a <strong>2L bioreactor</strong> strain to us for validation and
          training, helping us test parameters closer to industrial conditions.
          <br><br>
          Dr. Sprent also flagged that <strong>CRISPR licensing issues</strong> limit its use in commercial settings.  
          He proposed an alternative **split-marker double-crossover** system using a floxed episomal resistance marker
          removable by Cre recombinase — a method that avoids CRISPR dependencies and IP barriers.
          <br><br>
          Although we could not pivot in time to adopt this strategy within iGEM, it strongly influenced our
          understanding of <strong>open, IP-free yeast engineering</strong>.  
          Dr. Sprent later connected us to <strong>Mark Warner</strong> for further consultation on scale-up and
          downstream implementation, deepening our industry perspective.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Dr. Noah Sprent -->
<!-- SECTION START: Olivia Brown -->
<div id="olivia-brown" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Olivia Brown</span>
      </div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/olivia.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        At two key stages of our project, we consulted <strong>Olivia Brown</strong>, <strong>Entrepreneurship Advisor at
        the Imperial Enterprise Lab</strong>, to strengthen our <strong>business strategy and startup thinking</strong>.  
        Her expertise in <strong>market strategy and startup acceleration</strong> helped us connect scientific
        innovation to entrepreneurial execution.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Aimed to strengthen our <strong>entrepreneurial and business
              strategy</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Defined our <strong>customer base</strong> through ICP analysis and
            scalability potential.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Launched our <strong>market research strategy</strong> through
            stakeholder interviews and consumer surveys.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Gained access to the <strong>Expert Network</strong> and
            entrepreneurial support communities.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">
          In our first meeting early in the project, <strong>Olivia Brown</strong> encouraged us to think beyond the
          science and identify our <strong>business edge</strong>.  
          She asked key questions about who our customers are, what differentiates us, and how scalable our solution
          could become — pushing us to articulate not just feasibility, but market relevance.
          <br><br>
          Olivia stressed the importance of conducting <strong>market and competitor analyses</strong> before attempting
          any entrepreneurial outreach.  
          Following her advice, we designed a <strong>stakeholder interview plan</strong> and distributed
          <strong>consumer surveys</strong> to validate assumptions about growth-factor accessibility and cultivated-meat
          economics.
          <br><br>
          She also introduced us to several internal resources at Imperial — including the
          <strong>Startup Directory</strong>, <strong>Founder Slack community</strong>, <strong>EIT Food</strong>, and
          the <strong>Food Student Research Network</strong> — all of which expanded our network and helped us connect
          with potential collaborators and mentors.
          <br><br>
          In our second consultation, closer to the Jamboree, Olivia helped us refine our <strong>pitch presentation</strong>.
          She emphasised maintaining a balance between <strong>scientific credibility and business clarity</strong> and
          urged us to broaden our framing beyond cultivated meat to include wider biomanufacturing applications.  
          This pivot positioned our work as a **flexible production platform** rather than a single-industry product,
          improving our narrative for potential investors.
          <br><br>
          Olivia also guided us through <strong>IP considerations</strong> and introduced us to the Enterprise Lab’s
          <strong>Expert-in-Residence network</strong>, giving us access to over 100 specialists for targeted feedback.
          <br><br>
          Her mentorship helped bridge the gap between our technical research and business viability, ultimately shaping
          how we positioned the project for long-term impact.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Olivia Brown -->
 <!-- BEGIN REPLACE: #hugh-bowen (under #simulating-a-biotech-investor-pitch) -->
<div id="hugh-bowen" class="two-column-container timeline-event timeline-event-grey" style="margin-top: -0.1rem;">
  <div class=" timeline-dot"></div>
  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;"><span class="animate-text-scramble">Hugh Bowen</span></div>
      <div class="image-aligner-center">
        <img class="tilt-effect" src="https://static.igem.wiki/teams/5916/hp/hugh.webp" style="max-width: 70%;">
      </div>
    </div>
  </div>
  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">Meeting with <strong>Hugh Bowen</strong>, Senior Investor at SOSV, provided invaluable insights into how to refine both our <strong>pitch</strong> and broader <strong>strategy</strong>.</p>

      <p style="text-align: left;"><italic>Discussion Points:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color: white;">Aimed to gain <strong>investor-level feedback</strong> to refine our <strong>pitch</strong> and <strong>strategic positioning</strong>.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;"><strong>Clarified core offering</strong>, leading to a <strong>focused value proposition</strong> around growth factors.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;"><strong>Practised clearer, more cohesive storytelling</strong> of impact and feasibility.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color: white;">Developed a stronger <strong>stakeholder engagement</strong> and <strong>communication strategy</strong>.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span span class="text-glitch">Expand Interview.</span></h3>
      <div class="collapsible-content">
        <p style="text-align: left;">The session let us pressure-test an early-stage biotech idea with a seasoned investor, sharpening narrative, feasibility, and market framing. A key challenge was pinpointing <strong>what we truly offer</strong> — cultivated meat, growth factors, or chassis. We ultimately narrowed to <strong>growth factors</strong> applied to cultivated meat, yielding a simpler, more market-aligned proposition and better guidance for future stakeholder interactions (policy, accelerators, investors).</p>
        <div class="collapsible-close  collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>
<!-- END REPLACE: #hugh-bowen -->
<!-- SECTION START: Final Reflection -->
<div id="hp-reflection" class="two-column-container timeline-event timeline-event-grey">
  <div class="timeline-dot"></div>

  <div class="column-left">
    <div class="timeline-content">
      <div class="tagline-subline" style="text-align: center;">
        <span class="animate-text-scramble">Reflection & Integration</span>
      </div>
    </div>
  </div>

  <div class="column-right">
    <div class="timeline-content">
      <div class="spacer5"></div>

      <p style="text-align: left;">
        Across the course of our Human Practices journey, we moved from a team exploring yeast engineering to one
        designing for <strong>commercial and industrial relevance</strong>.  
        Through conversations with <strong>academic mentors, biomanufacturing experts, and investors</strong>, our
        project evolved from theoretical design to a <strong>scalable, manufacturable concept</strong>.
      </p>

      <p style="text-align: left;"><italic>Key Takeaways:</italic></p>
      <div class="justify-left">
        <ul>
          <li style="text-align:left; color:white;">Learned that <strong>scalability</strong> and
            <strong>regulatory context</strong> must guide experimental design from the beginning.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Recognised that <strong>downstream processing</strong> challenges are
            equally, if not more, important than yield improvement in industrial success.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Understood that <strong>open-source strain development</strong> is a
            crucial enabler of equitable and transparent biotechnology.</li>
          <div class="spacer"></div>
          <li style="text-align:left; color:white;">Shifted from an academic to an <strong>industry-informed mindset</strong>,
            shaping a project ready for translation beyond iGEM.</li>
        </ul>
      </div>

      <div class="spacer"></div>

      <h3 class="collapsible-trigger"><span class="text-glitch">Expand Reflection.</span></h3>
      <div class="collapsible-content">
        <p style="text-align:left;">
          Each consultation formed a node in our larger feedback network — where engineering design,
          ethical considerations, and entrepreneurial vision intersected.  
          <br><br>
          From <strong>Professor Kontoravdi’s</strong> insistence on designing for manufacturability, to
          <strong>Dr. Sprent’s</strong> advocacy for open bioprocess data, to <strong>Mark Warner’s</strong>
          perspective on realistic industrial limits, every expert reinforced that impactful synthetic biology is not
          defined by proof-of-concept success, but by <strong>deployability at scale</strong>.
          <br><br>
          This mindset change also redefined our approach to Human Practices:
          rather than viewing it as documentation, we came to see it as a
          <strong>core design process</strong> — one that transformed our strain engineering project into an
          ecosystem-ready platform concept.
          <br><br>
          Ultimately, Human Practices didn’t just complement our wet lab work — it <strong>redefined its purpose</strong>,
          guiding us to create something reproducible, scalable, and socially conscious.
        </p>
        <div class="collapsible-close collapsible-close-grey">Close</div>
      </div>
    </div>
  </div>
</div>

<div class="spacer5"></div>
<!-- SECTION END: Final Reflection -->
<!-- SECTION START: Final Page Closing -->
<div class="spacer5"></div>
  <!-- (end of timeline content) -->
  <div class="spacer3"></div>
</div> <!-- CLOSE .snake-timeline -->
<!-- SECTION START: Integrated Human Practices Award Consideration -->
<div class="page-section width-75" id="ihp-award">
  <div class="section-title ">
    <h1 style="text-align: left;" class="animate-text-scramble">Integrated Human Practices Award Consideration</h1>
  </div>

  <p style="text-align: left;">
    Through our Human Practices work, we have shown that our project goes beyond scientific research and contributes to
    public wellbeing by addressing:
  </p>
  <div class="spacer2"></div>
  <ul>
    <li style="text-align:left;"><strong>Responsibility and positive impact for the world: We directly addressed
        sustainability, accessibility, and ethical considerations.</strong> Our conversations with Reka Tron and Martin
      at Hoxton Farms were central for that.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Integration throughout the entire project lifecycle:</strong> by
      <strong>consulting stakeholders whenever we faced a design or strategic decision</strong>, and adapting our work
      in response, summarised in the main <strong>Discussion Points</strong> section of each conversation.
    </li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Thorough implementation:</strong> We have done so with clear context and
      rationale, by <strong>identifying the specific expertise we needed at each stage</strong>. Dr. Brigitte Gasser’s
      help is a great example, being a pioneering figure in <em>K. phaffii</em> engineering.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Incorporation of diverse views:</strong> We made sure to <strong>incorporate
        views of those sceptical of the future of our target segment</strong> to best address their concerns. This was a
      guiding principle in reaching out to experts in academia, up-and-coming founders, established industry players,
      VCs, lawyers, and academics, to ensure our design reflected multiple perspectives.</li>
    <div class="spacer"></div>
    <li style="text-align:left;"><strong>Thorough documentation of strategy:</strong> Key takeaways, and especially
      disagreements were integrated comprehensively so that future teams can use our learnings as inspiration,
      <strong>presenting a transparent record of our reasoning and outcomes</strong>.
    </li>
  </ul>
  <div class="spacer"></div>
  <p style="text-align: left;">
    Finally, by showing how Human Practices can fundamentally reshape a project, we hope we have created an inspiring
    example for future iGEM teams of <strong>how academia and industry outreach can be integrated in a way that sets
      realistic standards for the commercial implementation of synthetic biology technologies.</strong>
  </p>
</div>
<!-- SECTION END: Integrated Human Practices Award Consideration -->

<div class="spacer3"></div>

<!-- SECTION START: References -->
<div class="citation-block" id="citations">
  <h3>References</h3>
  <ol>
    <li>
      E. Swartz, “Cell culture media and growth factor trends in the cultivated meat industry,” The Good Food
      Institute, 2021.
    </li>
  </ol>
</div>
<!-- SECTION END: References -->
{% endblock %}
<!-- SECTION END: Final Page Closing -->